Benitec Biopharma Inc. Common Stock (BNTC)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn money, have durable advantages, and sell at a sensible price. Benitec does not yet fit that mold. It is a clinical-stage biotech with 24 employees and no revenue in the filed periods I can see. In fiscal 2026, the year ended 2026-06-30, it reported a net loss of $45.5 million, or diluted EPS of $-0.98. That was wider than fiscal 2025's $37.9 million net loss and fiscal 2024's $21.8 million loss, even though diluted EPS improved from $-1.22 to $-1.05 to $-0.98 as losses were spread over more shares. The quarterly filings for fiscal 2026 show continuing losses: $9.0 million in the quarter ended 2025-09-30, $11.8 million in the quarter ended 2025-12-31, and $11.9 million in the quarter ended 2026-03-31. Trailing free cash flow was negative $16.6 million, a negative 5.5% FCF yield, so the company consumes cash rather than produces it. On the positive side, debt is zero, beta is low at 0.27, and the Altman Z-Score of 31.26 suggests low balance-sheet distress risk on that measure. But the FairStock Score is 26/100, Piotroski is 1/9, and P/B is 1.68 at the 2026-10-13 close of $8.63. The Lynch screen assigns no category because the company has lost money in each of the last four years. Its only potential moat lies in its Silence and Replace platform, but that is unproven and not reflected in revenue. At a $301 million market cap, I see speculation, not a margin of safety.

In plain English: Benitec Biopharma is a tiny clinical-stage biotech with 24 employees trying to develop genetic medicines; it has not reported revenue in the filed periods shown. The business looks weak on current numbers because it keeps losing money and burned cash, though it carries no debt. At the 2026-10-13 close of $8.63, the $301 million market value looks expensive versus those current results unless its experimental medicines eventually succeed.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2026 10-Q (period ended 2025-12-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q4 2025 10-K (period ended 2025-06-30) · FY2026 10-K (period ended 2026-06-30) · FY2025 10-K (period ended 2025-06-30) · FY2024 10-K (period ended 2024-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer